Stereotaxis (STXS) Net Equity Issued and Repurchased (2014 - 2026)
Stereotaxis (STXS) posted quarterly Net Equity Issued and Repurchased of $4.9 million for Q1 2026, up 15065.62% year-over-year from N/an in Q1 2025, and down 38.15% quarter-over-quarter from $7.8 million in Q4 2025.
Stereotaxis (STXS) Net Equity Issued and Repurchased (2014 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Net Equity Issued and Repurchased for 13 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 15065.62% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $20.5 million (up 6748.49% YoY), while the FY2025 annual figure was $15.7 million, up 5171.38% from the prior year.
- Net Equity Issued and Repurchased fell to $4.9 million in Q1 2026 per STXS's latest filing, from $7.8 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $7.8 million in Q4 2025 and bottomed at -$26000.0 in Q2 2023.
- Historically, Net Equity Issued and Repurchased has averaged $1.2 million across 5 years, with a median of $54000.0 in 2022.
- Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased slumped 145.61% — and 2026, when it jumped 15065.62%.
- Stereotaxis' Net Equity Issued and Repurchased stood at $61000.0 in 2022, then plunged by 57.38% to $26000.0 in 2023, then jumped by 511.54% to $159000.0 in 2024, then jumped by 4835.22% to $7.8 million in 2025, then plunged by 38.15% to $4.9 million in 2026.
- Business Quant data shows STXS's Net Equity Issued and Repurchased at $4.9 million in Q1 2026, $7.8 million in Q4 2025, and $7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 29.31 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | - |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | - |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | - |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | - |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | 4.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.85 Mn |
| Mar 31, 2026 | 4.85 Mn |
| Dec 31, 2025 | 7.85 Mn |
| Dec 31, 2025 | 7.85 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |